Syndax Pharmaceuticals reveals data from phase 1 trial of axatilimab
Category: #health  By Nikita Chaurasia  Date: 2020-12-07
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Syndax Pharmaceuticals reveals data from phase 1 trial of axatilimab

According to reliable sources, Massachusetts-headquartered clinical stage biopharmaceutical company, Syndax Pharmaceuticals Inc. has revealed an updated data from its Phase 1 trial of its patent axatilimab. The company will reportedly present the data at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition and will be available on the company’s official website.

For the uninitiated, axatilimab is an investigational monoclonal antibody developed by Syndax Pharmaceuticals for targeting CSF-1R (colony stimulating factor-1 receptor), a protein that exists on cell surfaces and controls the functioning and survival of macrophages and monocytes. The antibody blocks the development of pulmonary chronic graft-versus-host disease (cGVHD) by mitigating the number of disease-mediating macrophages as well as their monocyte precursors.

The Phase 1 trials enrolled 15 participants, among which 67% patients displayed significant improvements in terms of symptoms, as measured by the Lee Symptom Scale score. Sources confirmed that the patients with refractory diseases were subjected to prior systemic therapies, including belumosudil, ruxolitinib and ibrutinib.

M.D. and CEO of Syndax Pharmaceuticals, Briggs W. Morrison was reported saying that axatilimab is the only agent developed for the treatment of cGVHD which specifically targets the monocyte-macrophage lineage, a key driver of the fibrotic disease process.

If reports are to be believed, Syndax plans on commencing the Phase 2 trials of axatilimab towards the end of 2020 to study the efficacy and safety of different doses of the antibody for treating cGVHD patients. The primary objective of the trials will be to assess the objective response rate based on the 2014 NIH consensus criteria for GVHD.

In other news, U.S.-based multinational pharmaceutical organization, Pfizer Inc. is reportedly planning on establishing an elaborate cold storage set up for maintaining the temperature integrity of its COVID-19 vaccine.

Source credits: https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-announces-additional-positive-data-from-phase-1-trial-of-axatilimab-in-patients-with-cgvhd-301186859.html

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Mercedes-Benz unveils the S-Class of EVs, comes with a 56-inch display

Mercedes-Benz unveils the S-Class of EVs, comes with a 56-inch display

By Nikita Chaurasia

Mercedes-Benz, a German multinational automaker of luxury and commercial vehicles, has unveiled its flagship electric sedan, the EQS. The new vehicle is likely to allow Mercedes to take on Tesla Inc., as the market for electric vehicles (EVs) continu...

Ford takes on GM, Tesla by debuting its first hands-free driving system

Ford takes on GM, Tesla by debuting its first hands-free driving system

By Nikita Chaurasia

Ford Motor Company, the American multinational automaker, is reportedly planning on introducing a hands-free driving feature on its 2021 Mustang Models as well as 2021 F-150 pickup truck through a software update, by the end of the year. The automob...

Oculus Quest 2 update to include wireless PC streaming, 120Hz mode

Oculus Quest 2 update to include wireless PC streaming, 120Hz mode

By Nikita Chaurasia

Oculus, a subsidiary of Facebook, Inc., that develops and manufactures virtual reality headsets, has recently announced that Oculus Quest 2’s new v28 software update will include native wireless desktop PC streaming as well as 120 Hz refresh ra...